152 results on '"Siccardi, Marco"'
Search Results
2. PA-727 Physiologically-based pharmacokinetic modelling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy
3. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin
4. Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study
5. Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy
6. Mechanisms of Drug Interactions II: Transport Proteins
7. Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
8. Correction to: Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
9. The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases
10. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
11. Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
12. Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy
13. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human
14. A Physiologically Based Pharmacokinetic Model to Predict Pegylated Liposomal Doxorubicin Disposition in Rats and Human
15. Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives
16. PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
17. Can the Dynamic External Pelvimetry Test in Late Pregnancy Reveal Obstructed and Prolonged Labor? Results From a Pilot Study
18. Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria
19. PBPK modelling of dexamethasone in patients with COVID-19 and liver disease
20. Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
21. List of Contributors
22. The Application of Nanotechnology to Drug Delivery in Medicine
23. In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel
24. Dynamic External Pelvimetry Test in Third Trimester Pregnant Women: Shifting Positions Affect Pelvic Biomechanics and Create More Room in Obstetric Diameters
25. Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles
26. Long-acting drugs and formulations for the treatment and prevention of HIV infection
27. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
28. The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development
29. Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug‐Drug Interaction Magnitudes in the Elderly
30. Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures
31. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
32. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling
33. A TWSTFT Transmitter Prototype Compatible with SDR Receivers and SATRE Modems
34. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics
35. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation
36. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz
37. Estimating the Mobility of the Michaelis Sacral Rhombus in Pregnant Women
38. Physiologically‐Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir‐Boosted Lopinavir
39. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling
40. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies
41. A Postural Approach to the Pelvic Diameters of Obstetrics: The Dynamic External Pelvimetry Test
42. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK
43. Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
44. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART
45. Improving maraviroc oral bioavailability by formation of solid drug nanoparticles
46. Towards a Maraviroc long-acting injectable nanoformulation
47. A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
48. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
49. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics
50. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.